- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02292836
Rosacea Prevalence in General Population - Pilot Study
Study Overview
Detailed Description
The study will test the subject questionnaire aimed to be used in a full general population prevalence study to screen potential subjects with rosacea.
Questionnaire will be self-administrated to Dermatology outpatients.
Testing will be performed at the practice of 2 Dermatologists experts in rosacea who will evaluate subjects' answers and propose fine-tuning of the questionnaire content, if needed.
Study Type
Enrollment (Actual)
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
- Male or Female aged between 18 (or locally accepted majority) and 65 years old both included.
- Subject visiting one of the study dermatology practices for daily care/routine dermatology consultation.
- Subject have to read and sign the approved Informed Consent form prior to any participation in the study,
- Subject willing and capable of cooperating to the extend and degree required by the protocol
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
rosacea patients
Questionnaire testing on routine dermatologist patient population
|
Questionnaire testing on rosacea and non-rosacea dermatology outpatients
|
|
non-rosacea patients
Questionnaire testing on routine dermatologist patient population
|
Questionnaire testing on rosacea and non-rosacea dermatology outpatients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sensitivity and specificity of questions
Time Frame: Day 1
|
sensitivity and specificity of each questionnaire key items by comparing subject answers and investigator assessments, as follows: Sensitivity= True Positive/(True Positive+False Negative) Specificity= True Negative/ (False Positive+True Negative) |
Day 1
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Fabien AUDIBERT, Bsc, Galderma R&D
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RD.03.SPR.29105
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rosacea
-
Amorepacific CorporationCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaKorea, Republic of
-
University of California, DavisCompletedRosacea | Ocular Rosacea | Cutaneous RosaceaUnited States
-
bioRASI, LLCCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Narrows Institute for Biomedical ResearchSun Pharmaceutical Industries LimitedRecruitingPapulopustular Rosacea | Papular-pustular Rosacea | Papulopustular Rosacea (PPR)United States
-
Actavis Inc.CompletedModerate to Severe Papulopustular RosaceaUnited States
-
Bionou Research, S.L.CompletedRosacea | Rosacea, Papulopustular | Rosacea Papular TypeSpain
-
Galderma R&DCompleted
-
Cutera Inc.CompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
University of MiamiCynosureLutronicRecruitingRosacea, Papulopustular | Rosacea, ErythematotelangiectaticUnited States
-
ISISPHARMANot yet recruitingRosacea Subtype 1 (Erythematotelangiectatic) | Rosacea, Erythematotelangiectatic
Clinical Trials on Questionnaire testing
-
M.D. Anderson Cancer CenterAstraZenecaCompleted
-
University of California, San FranciscoNational Cancer Institute (NCI)Active, not recruitingCervical Carcinoma | Human Papillomavirus-Related CarcinomaUganda
-
M.D. Anderson Cancer CenterCompletedMyelodysplastic Syndrome | Acute Myelogenous LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedAcute Graft Versus Host DiseaseUnited States
-
Memorial Sloan Kettering Cancer CenterCompleted
-
McMaster UniversityCompletedOsteopenia | Osteoporosis, PostmenopausalCanada
-
M.D. Anderson Cancer CenterAmerican Cancer Society, Inc.Completed
-
Ohio State University Comprehensive Cancer CenterCompletedLung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Cancer AJCC V8 | Stage IV Lung Cancer AJCC V8 | Stage IVA Lung Cancer AJCC V8 | Stage IVB Lung Cancer AJCC V8United States
-
University Children's Hospital, ZurichSanofiCompleted